Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL
Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL
Participants (N=10/group) will consist of non-treatment seeking individuals with AUD.

 Following informed consent and baseline screening, participants will partake in 3 stress
 induction sessions to assess their stress levels and cravings for alcohol. Participants will
 be randomized to receive either increasing doses of doxazosin XL (0, 4, and 8 mg) or placebo
 in a double-blind manner.
Inclusion Criteria:

 -  Meet DSM-5 criteria for AUD;

 -  Report excessive alcohol use as defined by CDC guidelines in the past month (>7
 drinks/week for woman, >14 drinks/week for men, >3 drinks/occasion for women>4
 drinks/occasion for men)3.

 Exclusion Criteria:

 -  Physical dependence on alcohol assessed using the SCID and Clinical Institute
 Withdrawal Assessment for Alcohol (CIWAA)41.

 -  Presenting an Alcohol Use Disorders Inventory (AUDIT) score indicative of severe
 alcohol dependence (≥13 for women, ≥15 for men);

 -  Meeting criteria for substance use disorder on drugs other than alcohol and nicotine;

 -  Currently taking a prescribed psychoactive medication (e.g., atomoxetine for ADHD). In
 addition, exclusion for those individuals taking CYP3A4 inhibitors. Most participants
 will not be taking any concomitant medications (including over-the-counter
 supplements). For those who are taking an allowed medication, the study physician will
 determine if the medications are CYP3A4 inhibitors.

 -  Medical conditions contraindicating doxazosin XL pharmacotherapy (e.g., postural
 hypotension);

 -  Taking contraindicated medications such as blood pressure medications;

 -  Be pregnant, nursing, or planning on becoming pregnant during the course of the study;

 -  Have any other illness, condition, or use of medications, which in the opinion of the
 PI and/or admitting physician would preclude safe and/or successful completion of the
 study.